ArticlePhysiological reports2017
Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine.
Article in Physiological reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pooled it
- Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study.Journal of ovarian research · 2019Trial
- The Bushen Huatan formula inhibits TP53-Mediated ferroptosis and modulating lipid metabolism in polycystic ovary syndrome abnormalities rat model.Journal of ovarian research · 2026Article
- Divergent pathophysiological drivers of polycystic ovary syndrome: insulin resistance independently fuels the hyperandrogenic phenotype whilst neuroendocrine factors dominate non-hyperandrogenic presentations.Frontiers in endocrinology · 2026Article
- Peripheral organ crosstalk in the regulation of ovarian endocrine function and reproductive homeostasis.Life medicine · 2025Review
- Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome.International journal of molecular sciences · 2023Review
- Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature.Frontiers in endocrinology · 2023Review
- The role of the thyroid in polycystic ovary syndrome.Frontiers in endocrinology · 2023Review
- Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease.Biomedicines · 2022Review
- Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications.Journal of clinical and translational hepatology · 2020Review
- Expression of angiopoietin-like protein 2 in ovarian tissue of rat polycystic ovarian syndrome model and its correlation study.Reproductive biology and endocrinology : RB&E · 2020Article
- Thyroid Hormone Analogues: An Update.Thyroid : official journal of the American Thyroid Association · 2020Review
- 3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?International journal of molecular sciences · 2020Review
- Novel thyroid hormones.Endocrine · 2019Review
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.Thyroid : official journal of the American Thyroid Association · 2019Review
- The Colorful Diversity of Thyroid Hormone Metabolites.European thyroid journal · 2019Review
- Effects of Repeated Sublethal External Exposure to Deep Water Horizon Oil on the Avian Metabolome.Scientific reports · 2019Article
- Similarities and Differences in the Peripheral Actions of Thyroid Hormones and Their Metabolites.Frontiers in endocrinology · 2018Review
- Beneficial effects of Heqi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2017Article
- Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine.Physiological reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Complex diseases such as polycystic ovary syndrome (PCOS) are associated with intricate pathophysiological, hormonal, and metabolic feedbacks that make their early diagnosis challenging, thus increasing the prevalence risks for obesity, cardiovascular, and fatty liver diseases. To explore the crosstalk between endocrine and lipid metabolic pathways, we administered 3-iodothyronamine (T1AM), a natural analog of thyroid hormone, in a mouse model of PCOS and analyzed plasma and tissue extracts using multidisciplinary omics and biochemical approaches. T1AM administration induces a profound tissue-specific antilipogenic effect in liver and muscle by lowering gene expression of key regulators of lipid metabolism, PTP1B and PLIN2, significantly increasing metabolites (glucogenic, amino acids, carnitine, and citrate) levels, while enhancing protection against oxidative stress. In contrast, T1AM has an opposing effect on the regulation of estrogenic pathways in the ovary by upregulating STAR, CYP11A1, and CYP17A1. Biochemical measurements provide further evidence of significant reduction in liver cholesterol and triglycerides in post-T1AM treatment. Our results shed light onto tissue-specific metabolic vs. hormonal pathway interactions, thus illuminating the intricacies within the pathophysiology of PCOS This study opens up new avenues to design drugs for targeted therapeutics to improve quality of life in complex metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.